Early success in GvHD sets up NDA for Kadmon’s lead

With its lead clinical candidate meeting the primary endpoint at an interim analysis of a pivotal trial for third-line chronic graft-versus-host disease, Kadmon plans to submit an NDA next year for KD025

Read the full 321 word article

How to gain access

Continue reading with a
two-week free trial.